Clinical Scorecard: Assessment of eribulin's effectiveness and safety in breast cancer patients with liver metastases: a retrospective analysis from real-world data
At a Glance
Category
Detail
Condition
Breast cancer with liver metastases
Key Mechanisms
Eribulin inhibits microtubule polymerization, leading to mitotic blockade and apoptotic cell death, while also remodeling tumor vasculature.
Target Population
Women aged ≥18 years with histopathologically confirmed metastatic breast cancer and liver metastases.
Care Setting
First Affiliated Hospital of Zhengzhou University, 2020-2024
Key Highlights
Median progression-free survival of 3.7 months.
Systemic objective response rate of 15.1%, with 21.2% in HR+/HER2− subtype.
Common adverse events included neutropenia (42.5%) and fatigue (37.0%).
No treatment-related deaths reported.
Study suggests preliminary activity of eribulin in heavily pre-treated patients.
Guideline-Based Recommendations
Diagnosis
Confirm liver metastases via radiological imaging (CT/MRI).
Histopathological confirmation of breast cancer required.
Management
Eribulin-based chemotherapy as a treatment option for BCLM.
Monitoring & Follow-up
Assess tumor response using RECIST version 1.1.
Monitor for adverse events during treatment.
Risks
Potential for neutropenia, fatigue, alopecia, and peripheral neuropathy.
Patient & Prescribing Data
Women with metastatic breast cancer and liver metastases.
Eribulin shows activity in patients heavily pre-treated with other therapies.
Clinical Best Practices
Consider eribulin for patients with liver metastases after prior treatments.
Regular monitoring for adverse effects is essential.
